Complete financial analysis of KalVista Pharmaceuticals, Inc. (KALV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of KalVista Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Aareal Bank AG (ARL.DE) Income Statement Analysis – Financial Results
- Bangkok Bank Public Company Limited (BBL.BK) Income Statement Analysis – Financial Results
- Check Point Software Technologies Ltd. (0Y9S.L) Income Statement Analysis – Financial Results
- Mynaric AG (0AR9.L) Income Statement Analysis – Financial Results
- Electronic Arts Inc. (0IFX.L) Income Statement Analysis – Financial Results
KalVista Pharmaceuticals, Inc. (KALV)
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 12.69M | 12.69M | 16.13M | 8.39M | 1.50M | 2.13M | 1.80M | 415.00K | 1.54M |
| Cost of Revenue | 86.17M | 802.00K | 743.00K | 651.00K | 40.19K | 35.02K | 18.24K | 12.67K | 14.66K | 8.29K | 0.00 | 0.00 |
| Gross Profit | -86.17M | -802.00K | -743.00K | 12.04M | 12.65M | 16.09M | 8.38M | 1.49M | 2.12M | 1.80M | 415.00K | 1.54M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 94.87% | 99.68% | 99.78% | 99.78% | 99.16% | 99.31% | 99.54% | 100.00% | 100.00% |
| Research & Development | 86.17M | 80.28M | 70.17M | 41.29M | 40.19M | 35.02M | 18.24M | 12.67M | 14.66M | 8.29M | 4.23M | 1.96M |
| General & Administrative | 54.28M | 30.60M | 26.45M | 16.64M | 13.03M | 10.93M | 8.86M | 11.18M | 2.65M | 1.61M | 1.40M | 1.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 54.28M | 30.60M | 26.45M | 16.64M | 13.03M | 10.93M | 8.86M | 11.18M | 2.65M | 1.61M | 1.40M | 1.41M |
| Other Expenses | -86.17M | 15.64M | 14.72M | 9.93M | 9.83M | 7.68M | 4.39M | 2.33M | 2.03M | 844.00K | -59.00K | 35.00K |
| Operating Expenses | 54.28M | 110.87M | 96.61M | 57.92M | 53.22M | 45.95M | 27.10M | 23.84M | 17.31M | 9.89M | 5.63M | 3.37M |
| Cost & Expenses | 140.45M | 110.87M | 96.61M | 57.92M | 53.22M | 45.95M | 27.10M | 23.84M | 17.31M | 9.89M | 5.63M | 3.37M |
| Interest Income | 0.00 | 2.23M | 1.09M | 903.00K | 1.83M | 1.40M | 82.00K | 36.00K | 50.00K | 19.00K | 2.00K | 1.00K |
| Interest Expense | 0.00 | 0.00 | 1.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 405.00K | 256.00K |
| Depreciation & Amortization | 816.00K | 802.00K | 743.00K | 651.00K | 525.00K | 378.00K | 180.00K | 40.00K | 133.00K | 38.00K | 27.00K | 38.00K |
| EBITDA | -134.28M | -92.11M | -81.60M | -45.59M | -40.02M | -29.44M | -18.53M | -22.30M | -15.15M | -8.05M | -5.25M | -1.76M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -458.89% | -312.48% | -182.87% | -201.94% | -1,573.80% | -788.05% | -446.29% | -1,264.10% | -114.37% |
| Operating Income | -140.45M | -110.87M | -96.61M | -57.92M | -40.53M | -29.82M | -18.71M | -22.34M | -15.18M | -8.09M | -5.22M | -1.83M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -456.45% | -319.41% | -184.91% | -222.84% | -1,485.31% | -711.72% | -448.39% | -1,256.87% | -119.18% |
| Total Other Income/Expenses | 5.35M | 17.96M | 14.27M | 11.68M | 11.29M | 9.13M | 2.90M | 3.74M | 3.75M | 863.00K | -462.00K | -220.00K |
| Income Before Tax | -135.10M | -92.91M | -82.34M | -46.24M | -29.24M | -20.69M | -15.81M | -18.60M | -11.44M | -7.23M | -5.68M | -2.05M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -364.41% | -230.42% | -128.31% | -188.29% | -1,236.90% | -536.15% | -400.55% | -1,368.19% | -133.49% |
| Income Tax Expense | -8.45M | -18.05M | -13.83M | -1.75M | -124.00K | 124.00K | -1.33M | -5.11M | -5.41M | -863.00K | 462.00K | 220.00K |
| Net Income | -126.64M | -74.85M | -68.51M | -44.49M | -29.12M | -20.82M | -15.81M | -18.60M | -11.44M | -7.23M | -5.68M | -2.05M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -350.62% | -229.44% | -129.08% | -188.29% | -1,236.90% | -536.15% | -400.55% | -1,368.19% | -133.49% |
| EPS | -3.44 | -2.68 | -2.80 | -2.33 | -1.64 | -1.38 | -1.53 | -1.92 | -2.40 | -6.17 | -7.83 | -2.83 |
| EPS Diluted | -3.44 | -2.68 | -2.80 | -2.33 | -1.64 | -1.38 | -1.53 | -1.92 | -2.40 | -6.17 | -7.83 | -2.83 |
| Weighted Avg Shares Out | 36.79M | 27.89M | 24.47M | 19.09M | 17.75M | 15.08M | 10.32M | 9.71M | 4.77M | 1.17M | 724.80K | 724.80K |
| Weighted Avg Shares Out (Dil) | 36.79M | 27.89M | 24.47M | 19.09M | 17.75M | 15.08M | 10.32M | 9.71M | 4.77M | 1.17M | 724.80K | 724.80K |
KalVista Pharmaceuticals Presents Data on Persisting Unmet Needs in Hereditary Angioedema at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that it presented real-world data from US patient surveys that assessed the experience of HAE patients using injectable on-demand treatments at the European Academy of Allergy and...
KalVista Pharmaceuticals Announces New England Journal of Medicine Publishes Oral Sebetralstat Phase 3 Data Demonstrating its Potential to Transform the Treatment Landscape for People with Hereditary Angioedema
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that late-breaking data from the pivotal phase 3 KONFIDENT trial and open label KONFIDENT-S extension trial evaluating the efficacy and safety of sebetralstat were presented as late-breaking...
KalVista Pharmaceuticals Announces Ten Abstracts Accepted for Presentation at the European Academy of Allergy and Clinical Immunology Congress 2024
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced the acceptance of multiple abstracts and a symposium at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024 taking place in Valencia, Spain from May...
KalVista Pharmaceuticals to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced its management will participate in fireside chats at the following...
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors granted ten newly-hired employees inducement options to purchase an aggregate of 94,000 shares of KalVista common stock on May...
KalVista Pharmaceuticals Highlights Strategic Plans for Coming Fiscal Year
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced its strategic plans for fiscal year 2025, beginning May 1, including for sebetralstat, the Company's investigational novel, oral plasma kallikrein inhibitor for the on-demand treatment of hereditary...
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that William C. Fairey has been appointed to the...
KalVista Pharmaceuticals to Present at 23rd Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced its management will participate in a fireside chat at the...
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $kalv--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that the compensation committee of KalVista's board of directors granted nine newly-hired employees inducement options to purchase an aggregate of 65,000 shares of KalVista common stock on...
KalVista Pharmaceuticals Presents Real-World Data on Burden of Treatment and HAE Attack Journey at the 2024 HAEi Regional Conference Americas
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that it presented multiple analyses of the relationship between...
Source: https://incomestatements.info
Category: Stock Reports